论文部分内容阅读
目的 :观察拓扑替康 (TPT)联合顺铂 (DDP)用于 / a期 SCL C术前新辅助化疗的效果及耐受性。方法 :85例 / a期 SCL C手术患者 ,术前接受新辅助化疗 ,其中 ,TPT组 4 9例 ,接受 TPT+DDP方案 ,与同期接受 VP- 16 +DDP方案 (VP- 16组 ) 36例作比较。结果 :TPT组 ,CR11例 ,PR2 8例 ,总有效率 79.6 % ;VP- 16组 ,CR8例 ,PR17例 ,总有效率 6 9.4 % ,两组有效率无显著性差异 (P>0 .0 5 ) ;化疗后肿瘤分期下降两组分别为 :TPT组 5 1.1% (2 5 / 4 9)例 ,VP- 16组 33.3% (12 / 36 )例 ,分期下降效果无显著性差异 (P>0 .0 5 ) ;两组不良反应主要为骨髓抑制 ,两组比较无统计学差异 (P>0 .0 5 )。结论 :TPT联合 DDP用于 SCL C术前新辅助化疗效果肯定 ,该方案可作为 SCL C术前新辅助化疗的一线方案
Objective: To observe the efficacy and tolerability of topotecan (TPT) plus cisplatin (DDP) in preoperative neoadjuvant chemotherapy for stage / a SCL. Methods: Eighty-five patients with stage SCL C surgery received neoadjuvant chemotherapy prior to surgery. Among them, 49 patients in the TPT group received TPT + DDP and 36 patients in the VP-16 + DDP group (VP-16) compared to. Results: The total effective rate was 79.6% in the group of TPT, CR11 and PR2. The total effective rate was 79.6% in VP-16 group, CR8 and PR17 cases, with a total effective rate of 9.44%. There was no significant difference between the two groups (P> 0.05) 5). After chemotherapy, the tumor stage decreased in two groups: 5 1.1% (25/49) in the TPT group and 33.3% (12/36) in the VP-16 group, with no significant difference in the staging effect (P> 0 .0 5). The two groups of adverse reactions were mainly myelosuppression. There was no significant difference between the two groups (P> 0.05). Conclusion: The combination of TPT and DDP for the preoperative neoadjuvant chemotherapy in SCL C is valid. This protocol can be used as a first-line solution for neoadjuvant chemotherapy before SCL C